Biopharma Vital Signs – Part 4: The New Partnership Playbook

Experts discuss how biopharma partnerships are evolving, as companies look beyond transactional supplier relationships toward more integrated, strategic, and collaborative models

July 10, 2026
15 min

The Medicine Maker

Original Source(s)

The Medicine Maker

Biopharma Vital Signs – Part 4: The New Partnership Playbook

July 10, 2026

Related Content

Frontiers In Immunology

Colorectal cancer liver metastases: mechanism and therapy

by Shan Liu, Liuxian Ban, Wei Zhang, Yutian Sun, Ke Wang, Yuxin Man, Yinjie Zhang
July 10, 2026

Frontiers In Oncology

Comparison of the diagnostic value of white light endoscopic, narrow band imaging, and iodine staining individually and in combination for early esophageal cancer and precancerous lesions

by Xia Yin, Miao Meng
July 10, 2026

Journal Of Neuro-Oncology

Leptomeningeal disease (LMD) after resection of brain metastases: results of the multicenter SUBAROMA study

by Laura Mühlhausen, Martin Kocher, Hanah Hadice Karadachi, Ulrich Sure, Yahya Ahmadipour, Levin Häni, Danial Nasiri, Tommaso Araceli, Martin Proescholdt, Nils Ole Schmidt, Andrea Cattaneo, Vera Nickl, Florian Scheichel, Franz Marhold, Stefan J. Grau, Christina A. Hamisch, Franz L. Ricklefs, Yahya Zghaibeh, Roland H. Goldbrunner, Stephanie T. Jünger
July 10, 2026